altimmune glp-1 Stock: is Its Drug Poised to Rival Ozempic? Altimmune ($ALT): Best-in-Class Tolerability, One
Description
Designed for 3ml vials approximately 17 mm in diameter and 38 mm tall
Are you ready
Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once monthly injection
Less than half do it in a way that protects their physiology
It's a generic version of the daily injectable Liraglutide.
In a recent survey, three-in-four respondents said they would prefer a oncedaily oral pill over a weekly injection of GLP-1s
